Q32 Bio Inc.
QTTB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661998
In the last 90 days, Q32 Bio Inc. insiders filed 0 open-market purchases and 3 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $282.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $275.1K in total
- 3
- 13F holdersQ2 2026, +19 vs. previous quarter
- 72
- 13F valueReported value at the end of Q2 2026
- $282.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding QTTB, Q2 2026
No superinvestor reported holding QTTB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Q32 Bio Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 (view filing)4:10 PM ET | Aug 25 | 2 days | Morrison Jodie PopeCEO | SSale | −9.85K | $16.56 | −$163.0K | −2.8%343.3K after | |
| Aug 27, 2026 (view filing)4:10 PM ET | Aug 25 | 2 days | Kalowski LeeCFO and President | SSale | −3.97K | $16.56 | −$65.8K | −2.8%138.5K after | |
| Aug 27, 2026 (view filing)4:10 PM ET | Aug 25 | 2 days | Violette Shelia M.Chief Scientific Officer | SSale | −2.80K | $16.56 | −$46.3K | −2.1%127.8K after | |
| Jun 1, 2026 (view filing)9:13 PM ET | May 28 | 4 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +1.88M | $8.00 | +$15.0M | New position625.0K after | 2 lotsDuplicate filing |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Xu DiyongDirector, 10% Owner | PPurchase | +1.88M | $8.00 | +$15.0M | New position625.0K after | 2 lots |
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Kalowski LeeCFO and President | SSale | −4.00K | $4.51 | −$18.0K | −10.0%35.9K after | |
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Morrison Jodie PopeCEO | SSale | −9.90K | $4.51 | −$44.6K | −10.0%89.1K after | |
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Violette Shelia M.Chief Scientific Officer | SSale | −2.81K | $4.51 | −$12.7K | −4.8%55.6K after | |
| Dec 4, 2025 (view filing) | Dec 2 | 2 days | Morrison Jodie PopeCEO | SSale | −22.5K | $3.46 | −$77.9K | −18.5%99.0K after | |
| Dec 4, 2025 (view filing) | Dec 2 | 2 days | Kalowski LeeCFO and President | SSale | −9.07K | $3.46 | −$31.4K | −18.5%39.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Q32 Bio Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 4,127,987 | $52.6M | 1.00% | +1,875,000+83.2% | Added |
| Boxer Capital Management, LLC | 3,149,310 | $40.1M | 3.02% | +3,149,310 | New |
| Atlas Venture Life Science Advisors, LLC | 2,717,106 | $34.6M | 3.93% | +625,000+29.9% | Added |
| BVF Inc | 2,350,000 | $29.9M | 0.77% | +2,350,000 | New |
| Ra Capital Management, L.P. | 2,332,457 | $29.7M | 0.26% | +2,332,457 | New |
| Point72 Asset Management, L.P. | 1,173,396 | $14.9M | 0.02% | +1,173,396 | New |
| Opaleye Management Inc. | 931,000 | $11.9M | 1.07% | −325,228−25.9% | Reduced |
| Logos Global Management LP | 800,000 | $10.2M | 0.44% | +800,000 | New |
| SummitTX Capital, L.P. | 733,774 | $9.35M | 0.25% | +733,774 | New |
| Vanguard Capital Management LLC | 518,803 | $6.61M | 0.00% | +212,402+69.3% | Added |